Stress Urinary Incontinence Clinical Trial
Official title:
Post Approval Study of the ProACTâ„¢ Adjustable Continence Therapy for Men
Verified date | May 2023 |
Source | Uromedica |
Contact | Patrick Gora |
Phone | 7636949880 |
pgora[@]uromedica-inc.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Status | Recruiting |
Enrollment | 145 |
Est. completion date | September 1, 2030 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is a male of at least 50 years of age. 2. Subject demonstrates stress urinary incontinence. 3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery. 4. Subject is willing and able to undergo surgical implantation of ProACT devices. 5. Subject is willing and able to comply with study-required follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies. 6. Subject is willing and able to sign the approved informed consent. 7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests). 8. Subject has a negative urine culture. 9. Subject has no known urogenital malignancy, other than previously treated prostate cancer. 10. Subject meets ONE of the following criteria: 1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL; 2. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA; 11. Physician determines subject to be a suitable surgical candidate. Exclusion Criteria: 1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy. 2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months. 3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo. 4. Subject has undergone radiation therapy in the prostatic area within the last 12 months. 5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity. 6. Subject has an atonic bladder. 7. Subject had, presently has, or is suspected of having bladder cancer. 8. Subject has untreated or unsuccessfully treated bladder stones. 9. Subject has detrusor sphincter dyssynergia. 10. Subject has known hemophilia or a bleeding disorder. 11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest). 12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | University of Colorado | Denver | Colorado |
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
Uromedica |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy | This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire".
This questionnaire will ask 3 questions regarding the ProACT therapy Did the ProACT therapy have a detrimental effect on the difficulty of the subsequent implant surgery? Did the ProACT therapy significantly increase the time required to implant the subsequent implant surgery? Did the ProACT therapy increase the surgical complication rate during the subsequent implant surgery? The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome. |
5 years | |
Primary | Urethral Strictures | Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up. | 5 years | |
Primary | Device Erosions | Cumulative incidence of ProACT device erosions over 5 years of follow-up. | 5 years | |
Primary | Incontinence Quality of Life Questionnaire (I-QoL) | Results on Validated Incontinence Quality of Life Questionnaire | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04829357 -
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
|
||
Completed |
NCT05493735 -
Lidocaine for Pessary Check Pain Reduction
|
Phase 3 | |
Completed |
NCT04512053 -
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
|
Phase 2 | |
Active, not recruiting |
NCT06224335 -
Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
|
||
Recruiting |
NCT05304312 -
The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women
|
N/A | |
Not yet recruiting |
NCT05527665 -
Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
|
||
Not yet recruiting |
NCT04558762 -
Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
|
||
Withdrawn |
NCT02524366 -
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
|
N/A | |
Completed |
NCT01924728 -
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01676662 -
Solace European Confirmatory Trial
|
N/A | |
Unknown status |
NCT01455779 -
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
|
N/A | |
Terminated |
NCT01029106 -
Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)
|
N/A | |
Withdrawn |
NCT00573703 -
Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence
|
Phase 4 | |
Completed |
NCT01770691 -
Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01123096 -
Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?
|
N/A | |
Completed |
NCT00234754 -
Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women
|
N/A | |
Completed |
NCT00441454 -
Retropubic vs. Transobturator Tension-free Vaginal Tape
|
N/A | |
Completed |
NCT03985345 -
Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.
|
N/A | |
Active, not recruiting |
NCT03671694 -
Laser Vaginal Treatment for SUI
|
N/A | |
Completed |
NCT04097288 -
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
|
Phase 1 |